Trial Profile
Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 Treatment
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 02 Nov 2021
Price :
$35
*
At a glance
- Drugs Favipiravir (Primary) ; Chloroquine
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- 01 Mar 2021 Primary endpoint (Need for mechanical ventilation) has not been met as per results published in the Archives of Virology.
- 01 Mar 2021 Primary endpoint (Number of patients with mortality) has not been met as per results published in the Archives of Virology.
- 01 Mar 2021 Status changed from recruiting to completed, as per results published in the Archives of Virology.